Screening rare genetic diagnoses for amenability to bespoke antisense oligonucleotide therapy development: a retrospective cohort study
David Cheerie, Marlen C. Lauffer, Logan Newton, Kimberly Amburgey, Danique Beijer, Bushra Haque, Brian Thomas Kalish, Margaret M. Meserve, Rachel Youjin Oh, Amy Y. Pan, Miriam S. Reuter, Michael J. Szego, Anna Szuto, Ana Lisa Taylor Tavares, Annemieke M Aartsma-Rus, , Evgueni A. Ivakine
The paper estimates the proportion of genetic diagnoses in a pediatric cohort that are amenable to antisense oligonucleotide therapy, finding 4.9% eligible or likely eligible.
Genetics in Medicine · Oct 11, 2025Peer-reviewedGenetic & Genomic Medicine